Organon & Co.
OGN
Hisse Senetlerindeki Sıralama
#4347
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Hisse Fiyatı
$13.80
Piyasa Değeri
$3.62B
Değişim (1 gün)
0.40%
Değişim (1 yıl)
49.35%
Ülke
US
Ticaret Organon & Co. (OGN)
Kategori
Healthcare
Organon & Co. (OGN) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 262.61M
Organon & Co. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 262.61M'dir. December 2024 sonunda şirketin 257.05M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Organon & Co. (OGN) için 2017 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 262.61M | 1.20% |
| 2025 | 259.50M | 0.95% |
| 2024 | 257.05M | 0.71% |
| 2023 | 255.24M | 0.46% |
| 2022 | 254.08M | 0.21% |
| 2021 | 253.55M | 0.01% |
| 2020 | 253.52M | 0.15% |
| 2019 | 253.13M | 0.00% |
| 2018 | 253.13M | 0.00% |
| 2017 | 253.13M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 892.40M | 239.82% |
US
|
|
| 2.45B | 832.01% |
US
|
|
| 1.77B | 574.38% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 203.11% |
CH
|
